These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19354002)

  • 21. Rosuvastatin: renal disorders and rhabdomyolysis.
    Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosuvastatin-induced rhabdomyolysis due to medication errors.
    Vodička M; Slanař O; Pisár M; Šálek T
    Ceska Slov Farm; 2020; 69(2):100-102. PubMed ID: 32545989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
    García Rodríguez LA; Herings R; Johansson S
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.
    de Kanter CT; Keuter M; van der Lee MJ; Koopmans PP; Burger DM
    Antivir Ther; 2011; 16(3):435-7. PubMed ID: 21555828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
    Wolfe S
    BMJ; 2015 Mar; 350():h1388. PubMed ID: 25787130
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
    Moreno A; Fortún J; Graus J; Rodriguez-Gandía MA; Quereda C; Pérez-Elías MJ; Nuño J; Wikman P; Moreno S; Bárcena R
    Liver Transpl; 2011 Mar; 17(3):331-3. PubMed ID: 21384516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
    McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A generalised sensation of coldness following introduction of rosuvastatin therapy.
    Huynh NT; Huot P
    BMJ Case Rep; 2014 Oct; 2014():. PubMed ID: 25301422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible acute hepatitis induced by rosuvastatin.
    Oteri A; Catania MA; Russo A; Salvo F; Giacci L; Caputi AP; Polimeni G
    South Med J; 2008 Jul; 101(7):768. PubMed ID: 19209117
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety of rosuvastatin.
    Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
    Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Takotsubo cardiomyopathy with involvement of delayed-onset rhabdomyolysis and acute kidney injury after rosuvastatin treatment.
    Kamada T; Hayashi M; Yokoi H; Fujiwara W; Yoshikawa D; Mukaide D; Sugishita Y; Yoshinaga M; Ito T; Ozaki Y; Izawa H
    Intern Med; 2015; 54(1):31-5. PubMed ID: 25742890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver toxicity of rosuvastatin therapy.
    Famularo G; Miele L; Minisola G; Grieco A
    World J Gastroenterol; 2007 Feb; 13(8):1286-8. PubMed ID: 17451217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
    Ferdinand KC
    Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of rosuvastatin on liver microsomal CYP2C6 in hereditary hypertriglyceridemic rat.
    Vecera R; Zacharová A; Siller M; Matuskova Z; Skottová N; Anzenbacherová E; Anzenbacher P
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():48-52. PubMed ID: 23353843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosuvastatin: an independent analysis of risks and benefits.
    Zipes DP; Zvaifler NJ; Glassock RJ; Gilman S; Muñoz A; Gogolak V; Gordis L; Dedon PC; Guengerich FP; Wasserman SI; Witztum JL; Wogan GN
    MedGenMed; 2006 Jun; 8(2):73. PubMed ID: 16926812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
    Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
    Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
    Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.